Research programme: macrocyclic peptide therapeutics - Eli Lilly/PeptiDream

Drug Profile

Research programme: macrocyclic peptide therapeutics - Eli Lilly/PeptiDream

Latest Information Update: 09 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; PeptiDream
  • Developer PeptiDream
  • Class Macrocyclic compounds; Peptides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 07 Mar 2016 Peptide discovery platform system (PDPS) technology non-exclusively licensed to Eli Lilly in USA
  • 19 Dec 2013 Early research in Undefined indication in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top